Iqbal, Arham, et al. “Benefits of Six Week and Personalized Dosing of Pembrolizumab Considering Ongoing Delta Variant Surge”. Journal of the Pakistan Medical Association, vol. 72, no. 3, Feb. 2022, doi:10.47391/JPMA.4660.